Lexaria Bioscience Corp. — Director's Dealing 2023

Oct 30, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lexaria Bioscience Corp. (LEXX)
CIK: 0001348362
Period of Report: 2023-10-26

Reporting Person: BUNKA CHRISTOPHER (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-10-26	Stock Options	$1.15	A	30000	Acquired	2028-10-26	Common Shares (30000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
common shares	273543	Direct
common shares	254412	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Warrants	$10.5	2025-05-06	Common Shares (6667)	6667	Indirect
Stock Options	$3	2026-04-26	Common Shares (26000)	32667	Direct
Stock Options	$3	2026-06-08	Common Shares (23334)	56001	Direct
Stock Options	$3	2026-09-01	Common Shares (15000)	71001	Direct
Stock Options	$2.91	2027-08-29	Common Shares (30000)	101001	Direct

Footnotes

F1: Repriced from $5.83 pursuant to shareholder approval received on May 9, 2023

F2: Repriced from $7.08 pursuant to shareholder approval received on May 9, 2023

F3: Repriced from $6.23 pursuant to shareholder approval received May 9, 2023